Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage II Breast Cancer: early-phase trial registry
5 of 31 indexed Stage II Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #495 of 28,707 conditions by registered trial count.
31 US clinical trials · 5 currently recruiting · #495 of 28,707 conditions by registered trial count
Stage II Breast Cancer: 31 US clinical trials tracked, 5 recruiting.
Stage II Breast Cancer is the subject of 31 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 4 of these trials.
Enrollment posture brief
Registry condition stage-ii-breast-cancer
OPEN 5 | RECR 16% | LATE 6 | EARLY 13 | RANK #495 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Dental Caries (16% recruiting · 31 trials)
Stage II Breast Cancer lists 5 open slots (16% of 31 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage II Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage II Breast Cancer is recruiting below its size-band peers.
5 of 31 indexed trials (16.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Stage II Breast Cancer trials is spread across many organizations.
Dana-Farber Cancer Institute accounts for 4 of 31 trials (12.9%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Stage II Breast Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 71 among the 31 trials that report a genuine target (sentinel values excluded). 19 of those (61.3%) plan for fewer than 100 participants.
-
Stage II Breast Cancer research is mostly interventional.
31 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
31 total, page 1 of 1
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
Dana-Farber Cancer Institute
NCT05535192
Improving Exercise Capacity With a Tailored Physical Activity Intervention
Wake Forest University Health Sciences
NCT05595577
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Jonsson Comprehensive Cancer Center
NCT04553770
A Study of Revaree Plus in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT07042581
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
Barbara Ann Karmanos Cancer Institute
NCT07095114
Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy
Alliance for Clinical Trials in Oncology
NCT01901094
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
NSABP Foundation
NCT01872975
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Alliance for Clinical Trials in Oncology
NCT01953588
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ECOG-ACRIN Cancer Research Group
NCT01824836
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
Alliance for Clinical Trials in Oncology
NCT03414970
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ECOG-ACRIN Cancer Research Group
NCT02445391
MARGetuximab Or Trastuzumab (MARGOT)
Dana-Farber Cancer Institute
NCT04425018
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
NCT02326974
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
NCT01750073
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
NCT04584255
Acupuncture Pilot Study for Cancer-related Cognitive Function
Memorial Sloan Kettering Cancer Center
NCT04007770
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
NCT02957968
Researching the Effect of Exercise on Cancer
Memorial Sloan Kettering Cancer Center
NCT04589468
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03387553
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
NCT00513292
Diindolylmethane in Treating Patients With Breast Cancer
University of Arizona
NCT01391689
Ask Questions (ASQ):Implementation of a Communication Intervention
Barbara Ann Karmanos Cancer Institute
NCT05025748
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Gary Morrow
NCT02002533
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
NCT00513695
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
NCT00470301
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Wake Forest University Health Sciences
NCT01869764
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
Craig A. Bunnell, MD, MPH
NCT00146588
Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer
National Cancer Institute (NCI)
NCT00516243
Living Well After Breast Surgery
University of Texas at Austin
NCT03834532
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01818063
Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT03102866
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 10 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage II Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage II Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage II Breast Cancer page
31 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Stage II Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Stage II Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage II Breast Cancer condition card totals 31 registered trials; most-linked intervention Paclitaxel; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.